123 related articles for article (PubMed ID: 2783958)
1. Abnormal proteolysis (DIC)--successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor.
Delshammar M; Lasson A; Nilsson IM; Ohlsson K; Wallmark A; Vernersson E
J Intern Med; 1989 Jan; 225(1):21-7. PubMed ID: 2783958
[TBL] [Abstract][Full Text] [Related]
2. Use of antithrombin concentrate in stable diffuse intravascular coagulation. A case report.
Haak HL; Stolk JC; Gratama JW; van Hulsteyn H; Briet E
Acta Haematol; 1982; 68(1):28-33. PubMed ID: 6812353
[No Abstract] [Full Text] [Related]
3. Liver disease in pregnancy with DIC and low levels of AT III.
Jespersen J
Scand J Haematol; 1983 May; 30(5):493-4. PubMed ID: 6857155
[No Abstract] [Full Text] [Related]
4. Observations during the treatment with antithrombin-III concentrate of a case of a tampon-related toxic shock syndrome and disseminated intravascular coagulation. Discrepancies between functional and immunologic determinations of antithrombin.
Jespersen J; Rasmussen NR; Toftgaard C
Thromb Res; 1982 Jun; 26(6):457-62. PubMed ID: 7112521
[No Abstract] [Full Text] [Related]
5. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial.
Maki M; Terao T; Ikenoue T; Takemura T; Sekiba K; Shirakawa K; Soma H
Gynecol Obstet Invest; 1987; 23(4):230-40. PubMed ID: 3111953
[TBL] [Abstract][Full Text] [Related]
6. Substitution therapy with an antithrombin III concentrate in shock and DIC.
Blauhut B; Necek S; Vinazzer H; Bergmann H
Thromb Res; 1982 Aug; 27(3):271-8. PubMed ID: 7135359
[TBL] [Abstract][Full Text] [Related]
7. [Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)].
Takahashi H; Hanano M; Takizawa S; Tatewaki W; Fuse I; Satoh K; Wada K; Shibata A
Rinsho Ketsueki; 1988 Mar; 29(3):336-43. PubMed ID: 3260969
[No Abstract] [Full Text] [Related]
8. Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.
Inocêncio G; Braga A; Azevedo S; Buchner G
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2857-9. PubMed ID: 24254552
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of disseminated intravascular coagulation with antithrombin III concentrate in children with verified infection].
Nowak-Göttl U; Groll A; Kreuz WD; Brand M; Breddin HK; von Loewenich V; Kornhuber B
Klin Padiatr; 1992; 204(3):134-40. PubMed ID: 1614177
[TBL] [Abstract][Full Text] [Related]
10. [Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation].
Vorob'eva NA; Neporada EL; Turundaevskaia OV; Mel'nikova GN
Anesteziol Reanimatol; 2007; (2):42-4. PubMed ID: 17563999
[TBL] [Abstract][Full Text] [Related]
11. [Fundamental studies on the management of disseminated intravascular coagulation (DIC) with antithrombin III (AT-III) concentrate].
Gotoh K
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr; 37(4):571-80. PubMed ID: 3989338
[TBL] [Abstract][Full Text] [Related]
12. Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation.
Yamada S; Okumura H; Morishita E; Asakura H
Blood Coagul Fibrinolysis; 2020 Jun; 31(4):274-278. PubMed ID: 32167951
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients.
Hellgren M; Javelin L; Hägnevik K; Blombäck M
Thromb Res; 1984 Aug; 35(4):459-66. PubMed ID: 6484893
[No Abstract] [Full Text] [Related]
14. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA
Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072
[TBL] [Abstract][Full Text] [Related]
15. Disseminated intravascular coagulation with multiple arterial thromboses responding to antithrombin-III concentrate infusion.
Wisecarver JL; Haire WD
Thromb Res; 1989 Jun; 54(6):709-17. PubMed ID: 2781511
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
17. [Use of antithrombin III concentrates].
Vinazzer H
Beitr Infusionsther; 1989; 24():151-8. PubMed ID: 2481532
[TBL] [Abstract][Full Text] [Related]
18. [Factor VIII (coagulation activity VIII:C, antigen concentration VIIIR:Ag and von Willebrand factor) in patients with clinically expected intravascular coagulation].
Tran TH; Lämmle B; Marbet UA; Ritz R; Marbet GA; Duckert F
Schweiz Med Wochenschr; 1981 Oct; 111(41):1542-3. PubMed ID: 6797063
[TBL] [Abstract][Full Text] [Related]
19. [The clinical efficacy of antithrombin III concentrate in infections complicated by DIC].
Kobayashi H; Kawai S; Oshitani H; Tamakuma S; Hayasaka H; Akiyama M; Nakamura T; Hashimoto I; Sawada Y; Takebe K
Kansenshogaku Zasshi; 1985 Nov; 59(11):1121-34. PubMed ID: 3938461
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
